Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
4(29%)
Results Posted
20%(1 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_2
4
29%
Ph not_applicable
2
14%
Ph phase_3
3
21%
Ph phase_1
5
36%

Phase Distribution

5

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
5(35.7%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
3(21.4%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

4

trials recruiting

Total Trials

14

all time

Status Distribution
Active(4)
Completed(5)
Terminated(1)
Other(4)

Detailed Status

Completed5
unknown4
Recruiting3
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
4
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (35.7%)
Phase 24 (28.6%)
Phase 33 (21.4%)
N/A2 (14.3%)

Trials by Status

recruiting321%
completed536%
unknown429%
terminated17%
active_not_recruiting17%

Recent Activity

4 active trials
Showing 5 of 14
recruitingphase_3

A Study of SHR-A1811 in Subjects With Ovarian Cancer

NCT06828354
recruitingphase_3

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

NCT07362914
active_not_recruitingphase_2

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

NCT04872985
recruitingphase_1

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

NCT06840002
completedphase_1

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

NCT06098599
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06828354Phase 3

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Recruiting
NCT07362914Phase 3

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions

Recruiting
NCT04872985Phase 2

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Active Not Recruiting
NCT06840002Phase 1

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

Recruiting
NCT06098599Phase 1

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Completed
NCT05354076Phase 2

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Unknown
NCT05273944Phase 1

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Unknown
NCT04983550Phase 2

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Unknown
NCT04460820Not Applicable

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Completed
NCT00632827Phase 2

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated
NCT03681548Phase 1

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Completed
NCT03017404Not Applicable

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Completed
NCT02912702Phase 3

L-DEP as an Initial Treatment for EBV-HLH

Unknown
NCT02260544Phase 1

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14